Navigation Links
Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results
Date:7/29/2010

ed "Two-Stage Phase I Dose-Escalation Study of Intratumoural Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers," in the online version of the journal Clinical Cancer Research that showed that 100% of 14 evaluable patients were stable disease or better (7 partial responses, and 7 stable disease); - A poster presentation at the American Association for Cancer Research's 101st Annual Meeting in Washington, DC entitled "Reovirus replication in ovarian and peritoneal tumors after intravenous administration," covering correlative results from a Phase 1/2 study with reovirus in patients with ovarian, primary peritoneal and fallopian tube carcinoma, sponsored by the National Cancer Institute under its Clinical Trials Agreement with Oncolytics;

Clinical Program

        -  Opening of enrollment in the Phase 3 trial examining REOLYSIN in
           combination with paclitaxel and carboplatin in patients with
           platinum-refractory head and neck cancers;
        -  Receipt of a No Objection Letter from Health Canada to conduct its
           Phase 3 trial examining REOLYSIN in combination with paclitaxel
           and carboplatin in patients with platinum-refractory head and neck
           cancers;
        -  Receipt of approval from the Belgian Federal Agency for Medicines
           and Health Products (FAMHP) to conduct its Phase 3 trial examining
           REOLYSIN in combination with paclitaxel and carboplatin in
           patients with platinum-refractory head and neck cancers;
        -  Start of enrollment in a U.S. Phase 2 clinical trial using
           intravenous administration of REOLYSIN in combination with
           gemcitabine (Gemzar(R)) in patients with advanced pancreatic
           cancer at the Cancer Therapy & Research C
'/>"/>
SOURCE  Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
2. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
5. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
6. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
7. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
8. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
9. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
10. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
11. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Verenium Corporation (Nasdaq: VRNM ), a leading ... of high-performance enzymes, today announced that Jeffrey ... two upcoming conferences. (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO ) ... Annual Marcum LLP Microcap Conference on Thursday, May 30, ... City.  The presentation is scheduled to begin at 4:30 ...
(Date:5/23/2013)... 23, 2013 Pusan National University Yangsan ... biotherapeutics and contract research company focused on research ... announced today a publication reporting the induction of ... oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex ... in the May 15 th , 2013 issue ...
(Date:5/23/2013)... May 23, 2013 African ... tracing for people of African descent, today announced ... offering. For people of all races, myDNAmix determines ... five distinct populations: Indigenous Americas (Native American), East ... Subcontinent. , Originally launched in late ...
(Date:5/23/2013)... 2013 Bed bugs compromised Penn ... already confirmed it. Meanwhile, My Cleaning Products offered complimentary samples ... fight the pests without using harmful chemical elements. , ... 2013, the affected building was actually a dormitory , ... said made on May 13 and bed bug presence was ...
Breaking Biology Technology:Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2
... Harriet L. Robinson, Ph.D., Chief Scientific Officer at ... in the development of HIV/AIDS vaccines, announced the results ... step closer to a vaccine that protects against multiple ... by Dr. Robinson during a presentation in Seattle at ...
... local product advancements and a strong 2012 research pipeline ... growth, Pioneer President Paul E. Schickler told ... "Global trends like an expanding middle class ... demand for food and require constant innovation, global science ...
... March 7, 2012 Palatin Technologies, Inc. (NYSE Amex: ... the 24th Annual ROTH OC Growth Stock Conference on Tuesday, ... will be held at the Ritz Carlton Laguna Niguel in ... and Chief Executive Officer of Palatin Technologies, will provide an ...
Cached Biology Technology:GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 2GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 3GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 4DuPont Leader Overviews 2012 Seed Research Pipeline with Investors 2DuPont Leader Overviews 2012 Seed Research Pipeline with Investors 3
(Date:5/21/2013)... Biologists have known for a long time that some ... well understood, particularly for plants. But it may be ... Australian National University and the U. S. National Evolutionary ... published 21 May in the journal Nature Communications ... faster-changing genomes. , Drawing from a database of global ...
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... cells in the blood often jump into action ... that can fight off illness. But repeated infections ... leading to the development of serious blood conditions ... led by biologists at the California Institute of ... the molecule microRNA-146a (miR-146a) acts as a critical ...
Breaking Biology News(10 mins):Small but speedy: Short plants live in the evolutionary fast lane 2Keeping stem cells strong 2
... issue of Sports Technology , published by ... the gap between able-bodied athletes and para-athletes, with ... first article, entitled "Biomechanics of double transtibial amputee ... al., compares the sprinting mechanics data of able-bodied ...
... patients with a particularly aggressive form of skin cancer ... from simply hearing that diagnosis, might amplify the progression ... that infers this also suggests that the use of ... of those tumors and therefore improve these patients, quality ...
... Entrust, Inc. (Nasdaq: ENTU ), a world leader in ... fiscal quarter and year ended December 31, 2008.Fourth-Quarter 2008, ... of $24.9 million, a decrease of 7% over Q4 2007; total ... million, an increase of 5%, adjusting for currency , ...
Cached Biology News:Stress may hasten the growth of melanoma tumors 2Stress may hasten the growth of melanoma tumors 3Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 2Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 3Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 4Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 5Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 6Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 7Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 8Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 9Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 10Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 11Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 12Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 13Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 14Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 15Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 16Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 17Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 18Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 19Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 20Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 21
Mycoplasma and virus tested...
... MagicMark and MagicMark XP Western Protein ... and convenient protein molecular weight estimation ... protein contains an IgG binding site, ... antibody-conjugate reagents used to detect your ...
... Immunogen: Synthetic peptide derived ... JAB1 (Jun activation domain-binding protein ... for the JAB1 protein. ... Jurkat cell lysates). Applications: ...
...
Biology Products: